San Francisco, CA—Percutaneous closure of the patent ductus arteriosus (PDA) in children using a novel device is safe and effective, according to a prospective study presented in a featured clinical ...
“This position statement represents a collective effort between neonatology, anesthesia, and interventional cardiology to provide comprehensive guidance on tcPDA device occlusion that can be adapted ...
In 2019, the U.S. Food and Drug Administration approved the first PDA occlusion device for infants as small as 700 grams, leading to rapid adoption of tcPDA in premature infants. Catheter-based ...
Extremely low birth weight (ELBW) infants with moderate to large patent ductus arteriosus (PDA) may benefit from transcatheter PDA closure (TCPC) in the first four weeks of life, according to research ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results